Open Access
BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea; NSC-409962) in the treatment of malignant brain tumor--a preliminary report.
Walker,Hurwitz Bs +1 more
- Vol. 54, Iss: 4, pp 263
Reads0
Chats0
About:
The article was published on 1970-08-01 and is currently open access. It has received 86 citations till now. The article focuses on the topics: Nitrosourea.read more
Citations
More filters
Book ChapterDOI
The Pharmacokinetics of ACNU in Patients with Malignant Brain Tumor
TL;DR: ACNU as discussed by the authors is a water-solube nitrosourea anticancer agent which has been developed in Japan and contains nitroso (-NO), alkyl (R-CH2-), and carbamoyl(R-N-CO) ligands.
Journal ArticleDOI
Scheduled Combination Chemotherapy of Adriamycin and BCNU to Malignant Brain Tumors
TL;DR: The 1 year survival rate of this chemotherapy with BAR therapy is better than that of BAR only in highly malignant glioma, and it is reasonable that the administration of Adriamycin and BCNU or CCNU is repeated every 8 weeks, assuming this combination chemotherapy results in 2 log kill.
Book ChapterDOI
1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in the Treatment of Primary Central Nervous System Tumors
TL;DR: Three groups of patients with CNS tumors were treated with BCNU, radiation and vincristine sulfate and only 1 patient of Group A is in very good condition at 6 months and 3 patients of Group B at 4 and 8 months.
Book ChapterDOI
Hirntumoren - Epidemiologie, Diagnostik und Methodik von Strahlen- und Chemotherapie
TL;DR: Dies gelingt auch durch transplazentare, parenterale, orale oder sogar ortliche Exposition gegenuber chemischen Karzinogenen (SWENBERG 1977).
Journal ArticleDOI
Chemotherapy, Volume 8: Cancer Chemotherapy 2
TL;DR: This second interim analysis reveals that intermittent treatment with levamisole 50 mg t.